2. Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE: JNJ) takes the No. 2 spot among the 10 Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds, and it remains one of the most established healthcare companies in the world. Trading at $254.66, with the stock up 3.99%, Johnson & Johnson (NYSE: JNJ) is backed by 113 hedge fund holders, reflecting strong institutional interest in a company that continues to operate across innovative medicine and medical technology. For investors looking for healthcare stocks to buy, dividend healthcare stocks, pharmaceutical stocks, medical device stocks, MedTech stocks, and AI-powered healthcare stocks, Johnson & Johnson (NYSE: JNJ) offers a rare mix of scale, brand history, global reach, and continued product innovation.
On June 6, Reuters reported that a Los Angeles jury found Johnson & Johnson (NYSE: JNJ) was not negligent in a lawsuit alleging that its talc products led to ovarian cancer in three women. The lawsuit was filed by the families of three women who died after using the company’s talc-based baby powder. Reuters also noted that more than 67,000 plaintiffs have filed similar lawsuits. Johnson & Johnson (NYSE: JNJ) stopped selling talc-based baby powder in the United States in 2020 and later switched to a cornstarch-based product. For investors, this legal update matters because talc litigation has been one of the longest-running overhangs on Johnson & Johnson (NYSE: JNJ). While one jury decision does not erase all litigation risk, favorable legal developments can help improve investor sentiment around the stock.
Separately, on June 15, Johnson & Johnson (NYSE: JNJ) announced the commercial launch of its Dual Energy THERMOCOOL SMARTTOUCH SF Platform in Europe. This platform is part of Johnson & Johnson (NYSE: JNJ)’s MedTech growth story and is designed for cardiac ablation procedures. The company said the platform delivers both radiofrequency and pulsed-field energy through a single catheter. That is important because physicians treating heart rhythm disorders need tools that are effective, adaptable, and precise. The platform also reported 12-month SmartFIRE data showing 86.9% effectiveness, giving Johnson & Johnson (NYSE: JNJ) a clinical performance point to support its launch.
Ricardo Martin, President of Johnson & Johnson (NYSE: JNJ), said the platform gives physicians “greater confidence to tailor treatment to each patient’s needs.” That statement points to one of the biggest trends in healthcare technology: personalization. Whether it is cancer treatment, diabetes care, diagnostics, surgery, or cardiac procedures, healthcare is moving toward tools that allow clinicians to match treatment more closely to each patient. A dual-energy platform that gives doctors more flexibility fits well into that theme. It also supports the broader narrative that Johnson & Johnson (NYSE: JNJ) is not just an old-line healthcare giant. It continues to launch advanced medical technology products that can support growth in specialized treatment areas.
The trivia behind Johnson & Johnson (NYSE: JNJ) is that many investors still associate the company with consumer health products, even though the company’s current focus is much more tied to innovative medicine and MedTech. After years of portfolio changes, Johnson & Johnson (NYSE: JNJ) is now better understood as a healthcare company with deep exposure to pharmaceuticals and medical technology. That shift matters for investors because these areas can offer stronger growth potential than slower-moving consumer products. It also helps explain why Johnson & Johnson (NYSE: JNJ) continues to appear in conversations about best healthcare stocks, medical device stocks, and long-term defensive growth stocks.
Johnson & Johnson (NYSE: JNJ) researches, develops, manufactures, and sells healthcare products through its Innovative Medicine and MedTech segments. For investors looking for best AI-powered healthcare stocks, healthcare stocks with institutional interest, medical technology stocks, pharmaceutical stocks, and long-term healthcare compounders, Johnson & Johnson (NYSE: JNJ) remains one of the most durable names in the sector. Legal risk remains part of the story, but the company’s MedTech launches and broad healthcare footprint keep it highly relevant for investors watching the next phase of medical innovation.
Click next to see the following stock...
